The Company participated in a fireside chat on Tuesday, June 11, 2019 at 2:00 p.m. Pacific Time. To access recording of audio webcast, click here
The Company hosted a conference call and live audio webcast on May 9, 2019, at 8:00 am Eastern Time. To access recording of this conference call, click here
We have assembled significant expertise in antibody engineering, particularly proprietary CDR-grafting methods, antibody production and formulation, immunochemistry, molecular biology, antibody conjugation, peptide chemistry, synthetic organic chemistry, and protein engineering.Our Science
We believe that each of our antibodies has therapeutic potential either when administered as a naked antibody or when conjugated with therapeutic radioisotopes (radiolabeled), chemotherapeutics, cytokines or other toxins to create unique and potentially more effective treatment options.Learn More
Immunomedics is sponsoring an international Phase 3 clinical trial in patients with relapsed triple-negative breast cancer who have previously received two or more therapies for their metastatic disease.